Shah, Manan P.
Neal, Joel W. http://orcid.org/0000-0003-3119-9334
Funding for this research was provided by:
Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, AbbVie
Article History
Accepted: 2 March 2022
First Online: 12 April 2022
Declarations
:
: No external funding was used in the preparation of this article.
: M.P. Shah declares that he has no conflicts of interest that might be relevant to the contents of this article. J.W. Neal declares the following: consulting or advisory role for AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics; research funding from Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, Janssen, and AbbVie.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MPS and JWN outlined the manuscript. MPS conducted literature review and composed the manuscript. MPS and JWN revised the manuscript.